TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00787462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
Study: NCT02076997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.
Study: NCT01187186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study: NCT00732277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
Study: NCT01787682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BOOST High Protein
Study: NCT01737476

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation. PFC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation. PFC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation. PFC

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation. PFC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation. PFC
Study: NCT00652366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib, escalating dose
Description: 100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib, standard dose
Description: 100mg, PO, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
Study: NCT00889265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CopiOs Pericardium Membrane
Description: CopiOs Pericardium, Puros Cancellous
Study: NCT04535349

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-body & CZT bone tracer imaging (SPECT)
Description: Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-body & CZT bone tracer imaging (SPECT)
Description: Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-body & CZT bone tracer imaging (SPECT)
Description: Quantitative analysis of myocardial uptake of 99mTc-labeled bone radiopharmaceuticals using new whole-body CZT-based SPECT-CT cameras
Study: NCT03034564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Northera

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT00867399

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-126
Description: See arm for details

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-126
Description: See arm for details
Study: NCT03061032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir 12W
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir plus Ribavirin 12W
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir 24W
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir plus Ribavirin 24W
Description: Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
Study: NCT06418607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Tablet-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Tablet-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Hard Capsule-Route of administration:Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat
Description: Pharmaceutical form:Hard Capsule-Route of administration:Oral
Study: NCT02428842

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tumor biopsies
Description: Tumor biopsies will be performed before and after treatment.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Blood sampling will be performed before and after treatment.
Study: NCT01238016

Intervention type: DEVICE
Group type: OTHER
Intervention: experimental
Study: NCT04247633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib at a dose of 125 mg will be administered orally once a day for 21 days, followed by 7 days off treatment of every 28 day cycle. Investigational medicinal product (IMP) will be administered with standard adjuvant endocrine therapy (Non-investigational treatment).
Study: NCT01732302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
Study: NCT01411436

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients who have received Nexavar for unresectable HCC
Study: NCT01841242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alcoholic povidone iodine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alcoholic chlorhexidine
Study: NCT02135211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Study: NCT02961621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Training for 9-1-1 Telecommunicators
Study: NCT01590550

Intervention type: PROCEDURE
Intervention: Use of citrate based dialysate
Description: Use of heparin free citrate based dialysate
Study: NCT03803059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SkinPen Precision
Description: Surgical instrument motors and accessories/attachments/Hydrogel
Study: NCT02511730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFDM Plus DBT
Description: FujiFilm Aspire Cristalle System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFDM
Description: FujiFilm Aspire Cristalle System
Study: NCT02509806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets 500 mg qd p.o.
Study: NCT02350972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cytokines
Description: Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
Study: NCT01731379

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
Study: NCT03008850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MgSo4
Description: Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.
Study: NCT00606203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: milnacipran
Description: taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00385502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
Description: nail lacquer applied daily for 48 weeks
Study: NCT06262958

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASSIST
Description: Adolescent psychiatric outpatient will be offered an e-form of ASSIST alcohol and substance use mini-intervention. Results will be compared to those who received TAU.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Psychotherapy and/or psychotropic drug treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Psychotherapy and/or psychotropic drug treatment
Study: NCT03957772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extrafascial injection
Description: Extrafascial injection of local anaesthetic under ultrasound guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrafascial injection
Description: Intrafascial injection of local anaesthetic under ultrasound guidance
Study: NCT02258451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)
Description: Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of NIST update)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Up to 6 cycles of saline injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: One 25 mg tablet once daily after a meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: One 25 mg tablet once daily after a meal.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Everolimus
Description: The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The recommended dose of everolimus administered in the study is 10 mg once daily with or without food.~Starting dose, dose modifications, and administration of exemestane and everolimus must be in compliance with the local labels in each of the participating countries and/or in line with local standard of practice.
Study: NCT03402529

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Contrast Enhanced Spectral Mammography
Description: Pilot study
Study: NCT02971462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ischemic conditioning
Description: In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
Study: NCT02860364

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest
Description: During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hypothermic circulatory arrest
Description: During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
Study: NCT02707783

Intervention type: DEVICE
Intervention: Bioresorbable vascular scaffold (BVS) implantation
Study: NCT04124913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 MG Oral Tablet
Description: Oral dydrogesterone 10 mg tablet three times a day for luteal phase support

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone Vaginal Gel [Crinone]
Description: Vaginal progesterone gel 90 mg once a day for luteal phase support
Study: NCT02652338

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNC-01
Description: twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
Study: NCT04066491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was received intravenously at a dose of 1000 milligram per meter square (mg/m\^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was received intravenously at a dose of 25 mg/m\^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
Study: NCT03650816

Intervention type: OTHER
Intervention: Doppler ultrasonography
Description: Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.

Intervention type: OTHER
Intervention: Doppler ultrasonography
Description: Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
Study: NCT02727985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist weaning schedule
Description: individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
Study: NCT03641963

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vittamed 205 Non-invasive intracranial pressure (ICP) meter
Description: Non-Invasive intracranial pressure measurement
Study: NCT01403818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide calcium hydrate
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitiglinide calcium hydrate
Description: oral
Study: NCT04186494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
Description: GLP-1 analogue treatment in combination with advice on diet and physical exercise

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure treatment
Description: Gold standard treatment for obstructive sleep apnea

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Liraglutide and CPAP
Description: Combination of both treatments
Study: NCT01803321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilonacept (IL-1 Trap)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilonacept (IL-1 Trap)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05146921

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-strain probiotic
Description: The intervention in this study is a multi-strain probiotic which contains four live strains of bacteria:~Lacticaseibacillus rhamnosus NCIMB 30174 Enterococcus faecium NCIMB 30176 Lactobacillus acidophilus NCIMB 30175 Lactiplantibacillus plantarum NCIMB 30173~10 billion colony-forming units (CFU) per 70 ml cup

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo similar in appearance and taste to the active intervention but with no active bacteria
Study: NCT03459911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozaar 100mg Tablet
Description: Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe \& Dohme B.V. , Haarlem, the Netherlands)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 100mg
Description: Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
Study: NCT00400881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automatic tube compensation
Description: new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
Study: NCT02838966

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestle IMPACT Advanced Recovery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestle IMPACT Advanced Recovery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestle IMPACT Advanced Recovery

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nestle Boost High Protein Drink
Study: NCT01034007

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tissue Engineered Vascular Grafts
Description: Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
Study: NCT02256514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daily oral dose of hepcortespenlisimut-L
Description: Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up